Search Articles

View query in Help articles search

Search Results (1 to 10 of 15 Results)

Download search results: CSV END BibTex RIS


Automated Process for Monitoring of Amiodarone Treatment: Development and Evaluation

Automated Process for Monitoring of Amiodarone Treatment: Development and Evaluation

Clinical background data were collected from patient records and stratified by the type of arrhythmia constituting indication for therapy. All patients received annual in-office appointments with a cardiologist for their clinical condition. Complementary follow-up with laboratory testing owing to the amiodarone treatment was carried out according to routine, irrespective of clinical follow-up.

Birgitta I Johansson, Jonas Landahl, Karin Tammelin, Erik Aerts, Christina E Lundberg, Martin Adiels, Martin Lindgren, Annika Rosengren, Nikolaos Papachrysos, Helena Filipsson Nyström, Helen Sjöland

J Med Internet Res 2025;27:e65473

Wearable Electrocardiogram Technology: Help or Hindrance to the Modern Doctor?

Wearable Electrocardiogram Technology: Help or Hindrance to the Modern Doctor?

This is particularly important, as the asymptomatic patient unaware of their arrhythmia will not present until serious sequelae (eg, stroke secondary to AF) occur. Furthermore, patients are often monitored for 24-48 hours, which has been shown to miss up to 30% of clinically significant arrhythmias [21]. Undoubtedly, consumer-owned smart technology negates many of these limitations. The question of efficacy remains.

Samuel Smith, Shalisa Maisrikrod

JMIR Cardio 2025;9:e62719

Scalable Approach to Consumer Wearable Postmarket Surveillance: Development and Validation Study

Scalable Approach to Consumer Wearable Postmarket Surveillance: Development and Validation Study

Af, afib, a-fib, a.fib, arrhythmia, paf, atrial fibrillation, a. fib, a fib, atrial fib, atrial arrhythmia, irregular heartbeat, irregular hr, irregular rhythm, irregular pulse, irreg hr, irregular heart beat, irregular heart rhythm, irregular heart rate, irreg heart rhythm, irreg heart beat, irreg heart rate, abnormal ekg rhythm, paroxysmal atrial fibrillation, a. fib, a - fib, pafib, abnormal heart rhythm, abnormal rhythm, abnormal HR, and arrhythmia Notes that were probabilistically labeled by the labeler

Richard M Yoo, Ben T Viggiano, Krishna N Pundi, Jason A Fries, Aydin Zahedivash, Tanya Podchiyska, Natasha Din, Nigam H Shah

JMIR Med Inform 2024;12:e51171

Cancer and Atrial Fibrillation Comorbidities Among 25 Million Citizens in Shanghai, China: Medical Insurance Database Study

Cancer and Atrial Fibrillation Comorbidities Among 25 Million Citizens in Shanghai, China: Medical Insurance Database Study

Atrial fibrillation (AF) is the most prevalent arrhythmia and affects approximately 1% of the general population [1,2]. Besides its relation to cardiovascular complications and mortality, increased risk of various noncardiovascular diseases, including cancers, was evident in a population with AF [3]. Cancer is the leading cause of noncardiovascular deaths and is associated with increased major bleeding, intracranial hemorrhage, and arguably thromboembolic events in patients with AF [4-6].

Mu Chen, Cheng Li, Jiwei Zhang, Xin Cui, Wenqi Tian, Peng Liao, Qunshan Wang, Jian Sun, Li Luo, Hong Wu, Yi-Gang Li

JMIR Public Health Surveill 2023;9:e40149

The Australian Genetic Heart Disease Registry: Protocol for a Data Linkage Study

The Australian Genetic Heart Disease Registry: Protocol for a Data Linkage Study

Eligibility criteria include a confirmed diagnosis of any inherited cardiomyopathy (HCM, dilated cardiomyopathy, arrhythmogenic cardiomyopathy, and restrictive cardiomyopathy), left ventricular noncompaction, or primary arrhythmia syndromes (long QT syndrome, Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia; Table 1) or at-risk relatives of those with a confirmed diagnosis.

Alexandra Butters, Bianca Blanch, Anna Kemp-Casey, Judy Do, Laura Yeates, Felicity Leslie, Christopher Semsarian, Lee Nedkoff, Tom Briffa, Jodie Ingles, Joanna Sweeting

JMIR Res Protoc 2023;12:e48636

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

Corrected QT Interval (QTc) Diagnostic App for the Oncological Routine: Development Study

An increased QTc of 10 ms contributes to a 5% to 7% exponential increased risk to develop the life-threatening arrhythmia Td P. Thus, a QTc of 540 ms exposes the patient to a 63% to 97% higher Td P risk than a QTc of 440 ms, but there is no QTc value at which Td P certainly occurs [29-31]. In the case of drug-induced LQTS with a QTc increased to >500 ms or a QTc prolongation of >60 ms above the baseline, treatment discontinuation or alternative therapies should be considered [1].

Kristina Klier, Yash J Patel, Timo Schinköthe, Nadia Harbeck, Annette Schmidt

JMIR Cardio 2023;7:e48096

Continuous mHealth Patch Monitoring for the Algorithm-Based Detection of Atrial Fibrillation: Feasibility and Diagnostic Accuracy Study

Continuous mHealth Patch Monitoring for the Algorithm-Based Detection of Atrial Fibrillation: Feasibility and Diagnostic Accuracy Study

A commercial arrhythmia analysis software (Awario, Heart2 Save) was used for automatic AF screening from the HRV data. The AI arrhythmia detection algorithm classified the HRV data in 30-second time windows into 3 categories: SR, AF, and uninterpretable. The accuracy of the AI-based rhythm classification from the HRV recording was further assessed by comparing it with the gold standard Holter ECG recording.

Onni E Santala, Jukka A Lipponen, Helena Jäntti, Tuomas T Rissanen, Mika P Tarvainen, Tomi P Laitinen, Tiina M Laitinen, Maaret Castrén, Eemu-Samuli Väliaho, Olli A Rantula, Noora S Naukkarinen, Juha E K Hartikainen, Jari Halonen, Tero J Martikainen

JMIR Cardio 2022;6(1):e31230

Surveillance of Arrhythmia in Patients After Myocardial Infarction Using Wearable Electrocardiogram Patch Devices: Prospective Cohort Study

Surveillance of Arrhythmia in Patients After Myocardial Infarction Using Wearable Electrocardiogram Patch Devices: Prospective Cohort Study

The majority of patients with acute myocardial infarction develop some form of arrhythmia during or immediately after the events, and more than 10% of these patients manifest serious arrhythmias such as ventricular tachyarrhythmias or atrial fibrillation, which may cause disabling stroke and sudden cardiac death [2,3]. These adverse events most frequently occur during the first months after myocardial infarction [4].

Ju-Seung Kwun, Chang-Hwan Yoon, Sun-Hwa Kim, Ki-Hyun Jeon, Si-Hyuck Kang, Wonjae Lee, Tae-Jin Youn, In-Ho Chae

JMIR Cardio 2022;6(1):e35615

Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study

Comparison Between the 24-hour Holter Test and 72-hour Single-Lead Electrocardiogram Monitoring With an Adhesive Patch-Type Device for Atrial Fibrillation Detection: Prospective Cohort Study

Reference 9: Yield and consistency of arrhythmia detection with patch electrocardiographic monitoring acquisition, and diagnostic performance of a novel adhesive patch for ambulatory cardiac rhythm monitoring in arrhythmia Reference 11: Ambulatory Arrhythmia Detection with ZIO® XT Patch in Pediatric Patients: A ComparisonarrhythmiaCardiac Arrhythmia, Atrial Fibrillation

Soonil Kwon, So-Ryoung Lee, Eue-Keun Choi, Hyo-Jeong Ahn, Hee-Seok Song, Young-Shin Lee, Seil Oh, Gregory Y H Lip

J Med Internet Res 2022;24(5):e37970